Home | Volume 12 | Article number 46

Case report

Poorly differentiated thyroid carcinoma: a case report

Poorly differentiated thyroid carcinoma: a case report

Mossab Tayane1,&, Mohammed Mliha Touati1, Mohammed El Akhiri1, Abdelfattah Aljalil1, Iliass Benchafai1, Younes Chebraoui1, Youssef Darouassi1, Haddou Ammar1


1Ear, Nose and Throat Department, Avicenna Military Hospital, Marrakech, Morocco



&Corresponding author
Mossab Tayane, Ear, Nose and Throat Department, Avicenna Military Hospital, Marrakech, Morocco




Poorly differentiated thyroid carcinoma (PDTC) is a new entity of thyroid cancers following the WHO classification of 2004, then it was a subject of debate for many years in order to establish its diagnosis criteria. Those tumors are known by their profile which is intermediate between the anaplastic thyroid carcinoma (ATC) end the differentiated thyroid carcinoma clinically and histologically, so we report this case of an asymptomatic patient diagnosed with a PDTC with distant metastasis concerning lungs and brain locations. To stratify the tumor, we related to the 8th version of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging system, which considers the ATC and PDTC as stage IV. we aim to discuss this case report in the light of literature, and the recommendations of the American thyroid association.



Introduction    Down

The poorly differentiated thyroid carcinoma (PDTC) was described in 1983, and since then, those tumors was a subject of discussion, on their morphological diagnosis features, molecular profile, and their clinical evolution. First of all, it was described as an intermediate tumor between Anaplastic Thyroid Carcinoma (ATC) and Differentiated Thyroid Carcinoma (DTC), introduced in the WHO classification of endocrine tumors as a new entity [1]. Then more features and diagnosis criteria were proposed by Memorial Sloan Kettering Cancer Center (MSKCC) in 2006 and adopted in the Turin proposal to set universal diagnosis criteria [2].

There is no specific stratification of tumor for the PDTC, the system of staging commonly used is the 8th version of the AJCC/UICC staging system, which consider the PDTC and ATC those ones as stage IV [3]. The American Thyroid Association (ATA) has established some guidelines to treat thyroid tumors, based on the staging system and the molecular profile of those tumors. We report a case of PDTC with aggressive features clinically, pulmonary and cerebral metastasis. and discussing the pathology with some review of the literature.



Patient and observation Up    Down

Patient information and timeline: our case is about a 54-year-old male patient, with no background of pathology, neither therapeutic intervention nor familial history of cancers, consulting for a neck tumor, progressing for about 6 months, situated cervical anterior, moving up and down with the swallowing, with a firm consistency. It was about a swelling of the thyroid gland, without any clinical signs of hyperthyroidism or hypothyroidism. Moreover, the patient reported a notion of chronic cough for 4 months.

Clinical findings: the examination of the cervical lymphatic nodes found a 2cm node situated in the left IIa territory, with a hard consistency. The pulmonary and neurological examinations were normal.

Diagnostic assessment: the cervical ultrasound check found a multinodular goiter with some EUTIRADS 3 and 5 nodes. The thyroid gland was considerably enlarged responsible for compression of the trachea and esophagus. Fine needle aspiration was done among the most scored thyroid node, and its cytological diagnosis was in favor of a Bethesda 3. However, in order to establish a diagnosis, we were in the obligation to make a biopsy, which was done surgically. Its histological features were in favor of a poorly differentiated thyroid carcinoma. In order to make a lesion assessment, a TAP CT found a voluminous goiter among the left lobe, with microcalcifications, compressing the aerodigestive axis (Figure 1). Moreover, it found some metastatic pulmonary localizations, and mediastinal nodes (Figure 2, Figure 3); also, a cerebral MRI was done in the profit of our patient, which localized some supra and subtentorial lesions with a secondary appearance compressive at the level of the posterior cerebral fossa (Figure 4), with the onset of an engagement.

Therapeutic intervention: we consulted the neurosurgical team about the cerebral localization, they decided to prescribe an anticomitial medication with full abstention from any kind of surgical intervention. The case was presented in a multidisciplinary meeting, gathering the neurosurgical, oncology, and endocrinology teams, who decided to indicate exclusive radiotherapy with anti-comitial medication as the primary prevention of epileptic seizures. However, the patient underwent a tracheostomy premiere.

Outcomes: the treatment proposed to our patient aimed to improve the quality of life and extend the survival of the patient. For this purpose, he was addressed to an oncology-radiotherapy center.

Informed consent: as a medical team, we communicated with the patient and informed him about our intention to publish his case. He was consentient and aware of the fact that his identity will be respected and preserved, also that there may be no benefits from this publication.

Patient’s perspective: “I was informed by the medical team about my condition, and the decision of the multidisciplinary meeting. I trust their decisions and I will follow the instructions given to me in the perspective of being cured of my cancer and extend my life expectancy.”



Discussion Up    Down

The PDTC was first described in 1983 as a carcinoma whose behavior was intermediate between well-differentiated thyroid carcinomas (WDTC) and anaplastic thyroid carcinoma (ATC) in terms of its clinical evolution and pathological features defined as a thyroid-globulin-producing non-follicular non-papillary carcinoma. It is considered a histological entity since 2004 according to the WHO classification of endocrine organ tumors [1]. This classification situated the PDTC between the WDTC and the ATC as an intermediate histological type. However, this classification was based on both architectural and high-grade features, which means a non-follicular and non-papillary growth pattern on the first hand, and a high mitotic index, invasive growth, and necrosis on the other hand [4]. Since then, the diagnostic criteria were debated as the old criteria were overlapped by other tumors with the same features or pattern of growth. A proposal was established by the Memorial Sloan Kettering Cancer Center (MSKCC) in 2006, which excluded the growth pattern from the criteria, and defined the PDTC based on the mitotic index and the presence of necrosis in a tumor with pathological or immunohistochemical evidence of follicular differentiation; this definition was adopted by the Turin proposal to set universal diagnosis criteria [2,5]. Since then, the diagnosis criteria are: 1) solid or trabecular or insular growth pattern; 2) lack of nuclear features of papillary thyroid carcinoma required; 3) at least one of the following three features: mitotic index ≥3/10 HPFs, tumor necrosis, convoluted nuclei. Also, those criteria were adopted by the WHO in their classification of tumors of endocrine organs in 2017 [6].

As the diagnosis is established, adequate staging is required to decide about the treatment. The latest staging system commonly used is the American Joint Committee on Cancer and UICC staging system, it replaced the 7th edition of the AJCC/UICC staging system, and it had proven efficiency in terms of survival. Some variables were adjusted in the 8th edition to improve the discrimination between patients and was based on the epidemiological observations and the clinical evidence. However, the current stratifications and studies concern Differentiated Thyroid carcinoma (DTC), but still it could be used on ATC and PDTC. These are staged as IV straight away [3].

The American Thyroid Association has defined an algorithm as recommendations to treat thyroid carcinomas based on the stages of the tumor. As the PDTC was staged VI, the first option was surgery as far as it was resectable, however, if not, the new guidelines preconize genetic testing to look for a genetic mutation on the BRAFV600E gene [7]. Tumors with a BRAFV600E mutation showed an excellent response to Dabrafenib/Trametinib - which was a kinase inhibitor for BRAF mutation - with an overall response rate of 65% in multiple results reported [8,9]. The surgery after treatment was always indicated if possible. This aggressive multimodal treatment based on kinase inhibitors combined with surgery is now recommended by the ATA and showed a decent outcome of ATC and PDTC in terms of survival, in front of the refractoriness of those carcinomas to radio-Iodine. An experimental study conducted on ATC and PDTC patient-derived cells by Sabine Wächter et al. consists of examining the efficacy of two different tyrosine kinase inhibitors and histone deacetylase inhibitor (HDACI) panobinostat. It showed a reduction of cell-viability after prolonged treatment with sorafenib-selumetinib and panobinostat by nearly 100%, also regulated the radio-iodine retention in comparison with dabrafenib-trametinib [10].

Poorly differentiated thyroid carcinoma should also be a subject of a systematized algorithm, to help teams take charge and care the patients with this type of tumor, which is not available in the literature as it is a new entity of thyroid cancers. However, as with all cancers, the treatment remains multidisciplinary between laryngologists, oncologists, neurosurgeons, and endocrinologists.



Conclusion Up    Down

Our case was introduced in an interdisciplinary consultation meeting, which opted to a radiotherapy for the cerebral metastasis since the patient was not operable anymore. Our patient presented a quick evolution of the disease, with asymptomatic secondary locations, all those factors give evidence of the aggressiveness of the PDTC, less than the ATC but widely more than the DTC. We also put the light on the efficiency of the tyrosine kinase inhibitors combined with surgery as an aggressive approach, which is recommended by the ATA. Also, this topic is still a subject of experimental studies, studying the histone deacetylase inhibitor as a potential therapy of PDTC.



Competing interests Up    Down

The authors declare no competing interests.



Authors' contributions Up    Down

All the authors have read and agreed to the final manuscript.



Figures Up    Down

Figure 1: voluminous goiter with tracheal deviation

Figure 2: mediastinal and pulmonary metastasis 1

Figure 3: mediastinal and pulmonary metastasis 2

Figure 4: posterior cerebral fossa secondary location



References Up    Down

  1. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs. WHO classification of tumours. 2004. Google Scholar

  2. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007 Aug;31(8):1256-64. PubMed | Google Scholar

  3. Cavalheiro BG, de Matos LL, Leite AKN, Kulcsar MAV, Cernea CR, Kowalski LP. Survival in differentiated thyroid carcinoma: Comparison between the 7th and 8th editions of the AJCC/UICC TNM staging system and the ATA initial risk stratification system. Head Neck. 2021 Oct;43(10):2913-2922. PubMed | Google Scholar

  4. Volante M, Papotti M. Poorly Differentiated Thyroid Carcinoma: 5 Years after the 2004 WHO Classification of Endocrine Tumours. Endocr Pathol. 2010 Mar;21(1):1-6. PubMed | Google Scholar

  5. Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: A clinicopathologic study of 58 patients. Cancer. 2006 Mar 15;106(6):1286-95 PubMed | Google Scholar

  6. Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO classification of tumours of endocrine organs. International Agency for Research on Cancer (IARC). 2017. Google Scholar

  7. Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid. 2021 Mar;31(3):337-386. PubMed | Google Scholar

  8. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13. PubMed | Google Scholar

  9. Cabanillas ME, Ryder M, Jimenez C. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. Endocr Rev. 2019 Dec 1;40(6):1573-1604. PubMed | Google Scholar

  10. Wächter S, Wunderlich A, Roth S, Mintziras I, Maurer E, Hoffmann S et al. Individualised Multimodal Treatment Strategies for Anaplastic and Poorly Differentiated Thyroid Cancer. J Clin Med. 2018 May 15;7(5):115. PubMed | Google Scholar